• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CYP3A4 基因中的功能性多态性与汉族人群冠心病风险增加相关。

A functional polymorphism in the CYP3A4 gene is associated with increased risk of coronary heart disease in the Chinese Han population.

机构信息

Guangzhou General Hospital of Guangzhou Military Command, 111 Liuhua Road, Guangzhou, Guangdong, China.

出版信息

Basic Clin Pharmacol Toxicol. 2011 Mar;108(3):208-13. doi: 10.1111/j.1742-7843.2010.00657.x. Epub 2010 Dec 29.

DOI:10.1111/j.1742-7843.2010.00657.x
PMID:21199372
Abstract

CYP3A4 is a major member of the cytochrome P450 (CYP) enzymes which play crucial roles in cardiovascular diseases. Recently, a novel polymorphism in the CYP3A4 gene, IVS10+12G>A, named CYP3A41G (rs2242480), has been identified. The aim of this study was to evaluate the potential relationship between the CYP3A41G allele and the susceptibility of coronary heart disease (CHD). A total of 628 individuals (322 unrelated patients with CHD and 306 age- and sex-matched healthy controls) were investigated in the study. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to identify CYP3A41G. We also analysed the functional significance of IVS10+12G>A using the dual-luciferase reporter assay. The results showed that the frequency of the CYP3A41G allele was 0.290 and the CYP3A4*1G/1G genotype was 0.090 in the patients with CHD. The patients with the CYP3A41G/1G genotype had higher CHD risk, with an odds ratio (OR) of 3.84 (p=0.025; 95% CI=1.32-12.65) after adjustment for conventional risk factors. A gender-dependent difference was also observed. The CYP3A41G/1G frequency was significantly higher in female patients than in the controls (p=0.034, OR=3.02, 95% CI=1.04-8.70). Furthermore, the dual-luciferase reporter assay indicated that the A allele at IVS10+12G>A had a significantly higher transcriptional activity than the G allele. Our results imply that CYP3A41G contributes to the susceptibility of CHD in the Chinese Han population, which may be useful for the study of specific molecular pathogenesis for CHD.

摘要

CYP3A4 是细胞色素 P450(CYP)酶的主要成员,在心血管疾病中发挥着关键作用。最近,在 CYP3A4 基因中发现了一种新的多态性,即 IVS10+12G>A,命名为 CYP3A41G(rs2242480)。本研究旨在评估 CYP3A41G 等位基因与冠心病(CHD)易感性之间的潜在关系。本研究共纳入 628 名个体(322 名无关联的 CHD 患者和 306 名年龄和性别匹配的健康对照者)。采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)方法鉴定 CYP3A41G。我们还使用双荧光素酶报告基因检测方法分析了 IVS10+12G>A 的功能意义。结果显示,CHD 患者 CYP3A41G 等位基因频率为 0.290,CYP3A4*1G/1G 基因型频率为 0.090。携带 CYP3A41G/1G 基因型的患者 CHD 风险更高,调整传统危险因素后,优势比(OR)为 3.84(p=0.025;95%CI=1.32-12.65)。还观察到性别依赖性差异。女性患者 CYP3A41G/1G 频率明显高于对照组(p=0.034,OR=3.02,95%CI=1.04-8.70)。此外,双荧光素酶报告基因检测表明,IVS10+12G>A 处的 A 等位基因转录活性明显高于 G 等位基因。我们的研究结果表明,CYP3A41G 在中国汉族人群中与 CHD 的易感性有关,这可能有助于研究 CHD 的特定分子发病机制。

相似文献

1
A functional polymorphism in the CYP3A4 gene is associated with increased risk of coronary heart disease in the Chinese Han population.CYP3A4 基因中的功能性多态性与汉族人群冠心病风险增加相关。
Basic Clin Pharmacol Toxicol. 2011 Mar;108(3):208-13. doi: 10.1111/j.1742-7843.2010.00657.x. Epub 2010 Dec 29.
2
The effect of CYP3A4*1G allele on the pharmacokinetics of atorvastatin in Chinese Han patients with coronary heart disease.CYP3A4*1G等位基因对中国汉族冠心病患者阿托伐他汀药代动力学的影响。
J Clin Pharmacol. 2014 Apr;54(4):462-7. doi: 10.1002/jcph.229. Epub 2013 Nov 27.
3
CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients.CYP3A4*1G 基因多态性影响中国妇科患者 CYP3A 活性和芬太尼反应。
Eur J Clin Pharmacol. 2010 Jan;66(1):61-6. doi: 10.1007/s00228-009-0726-4. Epub 2009 Sep 26.
4
Association of CYP3A4*1G and CYP3A5*3 With the 1-year Outcome of Acute Ischemic Stroke in the Han Chinese Population.CYP3A4*1G和CYP3A5*3与中国汉族人群急性缺血性卒中1年预后的关联
J Stroke Cerebrovasc Dis. 2019 Jul;28(7):1860-1865. doi: 10.1016/j.jstrokecerebrovasdis.2019.04.013. Epub 2019 May 4.
5
CYP3A4 * 1G Genetic Polymorphism Influences Metabolism of Fentanyl in Human Liver Microsomes in Chinese Patients.CYP3A4 * 1G基因多态性对中国患者人肝微粒体中芬太尼代谢的影响
Pharmacology. 2015;96(1-2):55-60. doi: 10.1159/000433441. Epub 2015 Jun 12.
6
Effect of CYP3A4*1G on the fentanyl consumption for intravenous patient-controlled analgesia after total abdominal hysterectomy in Chinese Han population.CYP3A4*1G 对汉族人群全子宫切除术后静脉患者自控镇痛中芬太尼消耗的影响。
J Clin Pharm Ther. 2012 Apr;37(2):153-6. doi: 10.1111/j.1365-2710.2011.01268.x. Epub 2011 Apr 29.
7
Influence of CYP3A5*3 polymorphism and interaction between CYP3A5*3 and CYP3A4*1G polymorphisms on post-operative fentanyl analgesia in Chinese patients undergoing gynaecological surgery.CYP3A5*3 多态性及 CYP3A5*3 与 CYP3A4*1G 多态性相互作用对妇科手术患者术后芬太尼镇痛的影响。
Eur J Anaesthesiol. 2011 Apr;28(4):245-50.
8
CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin.细胞色素P450 3A4*1G多态性与阿托伐他汀的降脂疗效相关,但与辛伐他汀的降脂疗效无关。
Eur J Clin Pharmacol. 2008 Sep;64(9):877-82. doi: 10.1007/s00228-008-0502-x. Epub 2008 Jun 5.
9
Correlations between CYP3A4 polymorphism and susceptibility to breast cancer in Chinese Han population.CYP3A4 多态性与中国汉族人群乳腺癌易感性的相关性。
Int J Clin Oncol. 2019 Feb;24(2):179-188. doi: 10.1007/s10147-018-1346-8. Epub 2018 Sep 14.
10
CYP3A4*1G regulates CYP3A4 intron 10 enhancer and promoter activity in an allelic-dependent manner.CYP3A4*1G以等位基因依赖的方式调节CYP3A4内含子10增强子和启动子活性。
Int J Clin Pharmacol Ther. 2015 Aug;53(8):647-57. doi: 10.5414/CP202272.

引用本文的文献

1
Effect of Obesity on Pharmacokinetics of Lidocaine and its Active Metabolites in Chinese Patients Undergoing Laparoscopic Bariatric Surgery: A Prospective Clinical Study.肥胖对接受腹腔镜减肥手术的中国患者利多卡因及其活性代谢产物药代动力学的影响:一项前瞻性临床研究。
Clin Pharmacokinet. 2025 Jun 4. doi: 10.1007/s40262-025-01510-7.
2
CYP3A4 gene expression discloses individual differences in postoperative pain susceptibility and drug treatment response in patients with lung cancer.CYP3A4基因表达揭示了肺癌患者术后疼痛易感性和药物治疗反应的个体差异。
Int J Clin Exp Pathol. 2024 Sep 15;17(9):287-297. doi: 10.62347/FPMQ3141. eCollection 2024.
3
Rs420137, rs386360 and rs7763726 polymorphisms in fibronectin type III domain containing 1 are associated with susceptibility to coronary heart disease: Analysis in the Han population.
含III型纤连蛋白结构域1基因中的Rs420137、rs386360和rs7763726多态性与冠心病易感性相关:汉族人群分析。
Front Cardiovasc Med. 2022 Oct 6;9:964978. doi: 10.3389/fcvm.2022.964978. eCollection 2022.
4
Interplay of Vitamin D and CYP3A4 Polymorphisms in Endocrine Disorders and Cancer.维生素 D 与 CYP3A4 多态性在内分泌疾病和癌症中的相互作用。
Endocrinol Metab (Seoul). 2022 Jun;37(3):392-407. doi: 10.3803/EnM.2021.1349. Epub 2022 Jun 3.
5
Pharmacogenetics Based Dose Prediction Model for Initial Tacrolimus Dosing in Renal Transplant Recipients.基于药物遗传学的肾移植受者他克莫司初始给药剂量预测模型
Front Pharmacol. 2021 Nov 30;12:726784. doi: 10.3389/fphar.2021.726784. eCollection 2021.
6
Influence of and Polymorphisms on the Pharmacokinetics of Teneligliptin in Humans.[基因]多态性对替奈利汀在人体药代动力学中的影响。 需注意,原文中“Influence of and Polymorphisms”这里有缺失信息,推测可能是某些基因相关的多态性,以上是基于合理推测补充完整后的翻译。
Front Pharmacol. 2021 Aug 26;12:736317. doi: 10.3389/fphar.2021.736317. eCollection 2021.
7
The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients.细胞色素 P450 3A 基因多态性对溃疡性结肠炎患者他克莫司药代动力学的影响。
PLoS One. 2021 Apr 22;16(4):e0250597. doi: 10.1371/journal.pone.0250597. eCollection 2021.
8
Impact of genetic variants of selected cytochrome P450 isoenzymes on pharmacokinetics and pharmacodynamics of clopidogrel in patients co-treated with atorvastatin or rosuvastatin.选定细胞色素P450同工酶的基因变异对与阿托伐他汀或瑞舒伐他汀联合治疗的患者中氯吡格雷药代动力学和药效学的影响。
Eur J Clin Pharmacol. 2020 Mar;76(3):419-430. doi: 10.1007/s00228-019-02822-x. Epub 2020 Jan 2.
9
Analysis of Differentially Expressed Genes in Coronary Artery Disease by Integrated Microarray Analysis.通过集成微阵列分析对冠心病差异表达基因的分析。
Biomolecules. 2019 Dec 25;10(1):35. doi: 10.3390/biom10010035.
10
Pharmacogenetics of amfepramone in healthy Mexican subjects reveals potential markers for tailoring pharmacotherapy of obesity: results of a randomised trial.健康墨西哥受试者中美苯丙醇胺的药物遗传学研究揭示了针对肥胖症药物治疗的潜在标志物:一项随机试验的结果。
Sci Rep. 2019 Nov 28;9(1):17833. doi: 10.1038/s41598-019-54436-z.